文献速递浆细胞疾病

改良来那度胺、硼替佐米和地塞米松方案治疗不适合移植的多发性骨髓瘤的2期研究

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.
PubMed 文献 · Br J Haematol · 2018-05-08

本研究评估改良来那度胺-硼替佐米-地塞米松(RVD lite)方案在不适合移植的多发性骨髓瘤(MM)患者中的疗效与安全性。2013年4月至2015年5月筛查53例,50例接受至少一剂治疗,中位年龄73岁。总缓解率(ORR)86%,66%达非常好的部分缓解及以上,中位无进展生存期(PFS)35.1个月,中位随访30个月时中位总生存期(OS)未达到。

要点

  • RVD lite方案在不适合移植的MM患者中ORR为86%,66%达非常好的部分缓解及以上。
  • 中位PFS为35.1个月(95%CI 30.9-未达到),中位随访30个月时中位OS未达到。
  • 周围神经病变见于31例(62%)患者,仅1例出现3级症状。

核心结论

  • RVD lite方案在不适合移植的MM人群中耐受性好且高效,PFS和OS稳健。

研究设计与样本

  • 2期研究,评估改良来那度胺-硼替佐米-地塞米松(RVD lite)方案,35天为一周期。
  • 2013年4月至2015年5月筛查53例 eligble 患者,50例接受至少一剂治疗;中位年龄73岁(范围65-91)。

主要发现

  • ORR为86%,66%的患者达到非常好的部分缓解或更好。
  • 中位PFS为35.1个月(95%CI 30.9-未达到),中位随访30个月时中位OS未达到。
  • 周围神经病变报告于31例(62%)患者,仅1例出现3级症状。

关键数值与推荐

  • 来那度胺15 mg口服,第1-21天;硼替佐米1.3 mg/m2每周皮下注射,第1、8、15、22天;地塞米松20 mg口服,于硼替佐米给药当天及次日,共9周期,随后6周期来那度胺和硼替佐米巩固治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We sought a regimen that incorporates optimal novel agents and balances efficacy with toxicity in transplant-ineligible multiple myeloma (MM) patients. Our study evaluated modified lenalidomide-bortezomib-dexamethasone (RVD lite) in this population and was administered over a 35-day cycle. Lenalidomide 15 mg was given orally on days 1-21; bortezomib 1·3 mg/m2 weekly subcutaneously on days 1, 8, 15 and 22; and dexamethasone 20 mg orally was given on the day of and day after bortezomib for 9 cycles followed by 6 cycles of consolidation with lenalidomide and bortezomib. The primary objective was to evaluate the overall response rate (ORR); secondary objectives included safety, progression-free survival (PFS) and overall survival (OS). Fifty-three eligible patients were screened between April 2013 and May 2015; 50 received at least one dose of therapy. Median age at study entry was 73 years (range 65-91). The ORR was 86% and 66% of patients achieved a very good partial response or better. Median PFS was 35·1 months (95% confidence interval 30·9-not reached) and median OS was not reached at a median follow-up of 30 months. Peripheral neuropathy was reported in 31 (62%) patients with only 1 patient experiencing grade 3 symptoms. RVD lite is a well-tolerated and highly effective regimen, with robust PFS and OS, in the transplant-ineligible MM population.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. O'Donnell EK, Laubach JP, Yee AJ, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018. PMID: 29740809. doi:10.1111/bjh.15261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。